Rob Lin, PhD, CFA, is Vice President of Translational Programs at UPMC Enterprises. Dr. Lin joined the ITTC team in October 2017 to help commercialize UPMC’s immunotherapy research. Before UPMC, Dr. Lin worked for the Bill & Melinda Gates Foundation, leading the finance and strategy activities for the Global Health Program. Dr. Lin earned a PhD in Genetics at Harvard University and then transitioned into business and corporate development at Millennium Pharmaceuticals (now Takeda Oncology).